anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
High-Gradient Aortic Stenosis is defined as valve area \<1 cm2 and mean gradient \>40 mmHg by resting transthoracic echocardiography. All patients in this subgroup underwent TAVI. Data on aortic valve calcification is not mandatory for this control group.
With mild sedation, a continous bupivacaine 0.1% infusion catheter is placed in the adductor canal. Afterwards, patients are placed under General Anesthesia, and surgery starts. Preoperative, 2 hours and 24 hours stress biomarkers and analgesic quality will be measured.
BACKGROUND: Cardiac tumors have a low incidence in general population, and its clinical presentation varies so much. The aim of this clinical case report is to highlight the importance and utility of ultrasound and echocardiogram in the emergency department as a tool for diagnostic and therapeutic procedures.
CLINICAL CASE: 60-year-old male patient who presented to the emergency department because of dyspnea, dizziness, and weakness. At his arrival he was found with 35 bpm, and a junctional bradycardia was confirmed. We decided to implant a temporary transvenous pacemaker with the aid of ultrasound and echocardiogram guidance, finding an intracardiac left atrium mass compatible with a myxoma. The patient was admitted to the cardiology ward, with no remission of the bradycardia. The arrhythmia persisted, which is why the patient underwent the resection of the cardiac tumor along with an implant of a permanent epicardial DDDR pacemaker. The patient was discharged home after a few days with no complications, and he was doing well after a 30-day follow-up.
CONCLUSIONS: Diagnosis of cardiac tumors is sometimes obtained as an incidental finding with image diagnostic tests. In our case, the use of ultrasound in our emergency department as a diagnostic and therapeutic tool led us to document the cardiac tumor of our patient since his arrival to the hospital.
AIMS: Catheter ablation (CA) of atrial fibrillation (AF) improves left ventricular ejection fraction (LVEF) in patients with heart failure with reduced ejection fraction (HFrEF). The impact of ST-segment depression before CA on LVEF recovery and clinical outcomes remains unknown. In the present study, we aimed to investigate the relationship between ST-segment depression during AF rhythm before CA and improvement in the LVEF and clinical outcomes in persistent atrial fibrillation (PerAF) patients with HFrEF.
METHODS AND RESULTS: The present study included 122 PerAF patients (male; 98 patients, 80%, mean age: 69 [56, 76] years) from the Osaka Rosai Atrial Fibrillation ablation (ORAF) registry who had LVEF < 50% and underwent an initial ablation. The patients who underwent percutaneous coronary intervention or coronary artery bypass grafting within the past 1 month were not included in the enrolled patients. We assigned the patients based on the presence of ST-segment depression before CA during AF rhythm and evaluated improvement in the LVEF (LVEF ≥ 15%) 1 year after CA and the relationship between ST-segment depression and heart failure (HF) hospitalization/major adverse cardiovascular events (MACE), which are defined as a composite of HF hospitalization, cardiovascular death, hospitalization due to coronary artery disease, ventricular arrhythmia requiring hospitalization and stroke. The percentage of patients with improvement in the LVEF 1 year after CA was significantly lower in the patients with ST-segment depression than those without (58.6% vs. 79.7%, P = 0.012). Multiple regression analysis showed ST-segment depression was independently and significantly associated with improvement in the LVEF 1 year after CA (HR: 0.35; 95% CI: 0.129-0.928, P = 0.035). Kaplan-Meier analysis showed that the patients with ST-segment depression significantly had higher risk of HF hospitalization and MACE than those without (log rank P = 0.022 and log rank P = 0.002, respectively). Multivariable Cox proportional hazards analysis showed that ST-segment depression was independently and significantly associated with a higher risk of MACE (HR: 2.82; 95% CI: 1.210-6.584, P = 0.016).
CONCLUSIONS: ST-segment depression before CA during AF rhythm was useful prognostic predictor of improvement in the LVEF and clinical outcomes including HF hospitalization and MACE in PerAF patients with HFrEF.
PURPOSE: An apparatus for preparing customized cosmetics is provided to rapidly mix raw materials in an emulsion state by operating an ultrasonic wave vibrator using an ultrasonic wave generator. CONSTITUTION: A flow cell(10) includes a supplying tube(12) and a hollow path pipe(14). An ultrasonic wave generator(20) surrounds the external surface of the flow cell. An ultrasonic wave vibrator(30) generates and destroys bubbles in raw materials using the positive pressure and the negative pressure of the ultrasonic wave generator. A supporting stand(40) and a base(50) support the ultrasonic wave generator. A controller controls the supply of the raw materials and the drive of the ultrasonic wave generator.
Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
PURPOSE:To obtain an emulsifier composition of good quality by mixing specific ratios of oil phase components, water phase components, etc. then mixing these powerfully at high temps. CONSTITUTION:The base components compounded with 5-60wt% an oil phase component contg. higher fatty acids such as lauric acids, palmitic acids or the like and/or higher fatty acid-contg. matter, 40-90wt% a water phase component such as water or alcohol, and 0.5-5wt% clay ore having gelation capacity such as bentonite and controlled of pH to 4-10.5 are mixed, after which the mixture is powerfully agitated at high temps. to prepare an emulsifier composition. This emulsifier composition can be produced without using any surfactant, and since it is free from skin stimulus, and secular change, it is adapted as an emulsifier composition for cosmetics.
The invention belongs to the technical field of pharmaceutical chemistry and pharmacology, and discloses application of 2, 3, 6-trideoxyglycosyldiphyllin in preparation of an anti-tumor drug. The 2, 3, 6-trideoxyglycosyl diphyllin compound has a structure shown in a formula (I): intermediate 1 is obtained by reacting diphyllin with 3-bromopropanol or 6-bromohexanol. And carrying out allyl glycosylation reaction on the intermediate 1 and corresponding tert-butyl carbonate pyrazone to obtain an intermediate 2. And carrying out Luche reduction reaction on the intermediate 2 and sodium borohydride to obtain an intermediate 3. And carrying out palladium-carbon hydrogen reduction on the double bond of the intermediate 3 in methanol to obtain 2, 3, 6-trideoxyglycosyl diphyllin 4. The 2, 3, 6-trideoxyglycosyldiphyllin compound provided by the invention has stronger antitumor activity and can be used for preparing antitumor drugs.
Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
A peristaltic pump, and related method, are disclosed that includes a cam shaft, a plunger-cam follower, a tube receiver, a spring, a plunger, a door, and a plunger lift lever. The cam shaft includes a plunger cam. The plunger-cam follower engages with the plunger cam of the cam shaft. The spring provides a bias and the plunger is biased toward the tube receiver by the spring. The plunger is coupled to the plunger-cam follower where expansion of the plunger cam along a radial angle intersecting the plunger-cam follower as the cam shaft rotates actuates the plunger away from the tube receiver. The door lever can be actuated between a first position and a second position. The plunger lift lever is coupled to the door lever to actuate the plunger away from the tube receiver when the door lever is actuated to the second position.
PURPOSE:To obtain a dental adhesive containing a specific chlorinated solvent and a polycarbonate resin at a specific ratio, and capable of bonding a dental polysulfone resin firmly to a dental acrylic resin. CONSTITUTION:An adhesive containing (A) 100pts.wt. of a chlorinated solvent having a boiling point of 50-150 deg.C (e.g. ethylene chloride, chloroform, trichloroethylene, etc.) and (B) 0.3-20pts.wt., preferably 0.5-15pts.wt. of a polycarbonate resin (i.e. 4,4-dioxydiarylalkane polycarbonate) is used for the bonding of a dental polysulfone resin and a dental acrylic resin, e.g. bonding of a denture bed made of polysulfone resin and an artificial tooth made of an acrylic resin, a denture bed made of a polysulfone resin and a rebasing agent composed of an acrylic resin, a denture bed made of acrylic resin and an artificial tooth made of polysulfone resin, etc.
Heart failure (HF) with preserved ejection fraction (HFpEF) is an increasingly frequent form and is estimated to be the dominant form of HF. On the other hand, HFpEF is a syndrome with systemic involvement, and it is characterized by multiple cardiac and extracardiac pathophysiological alterations. The increasing prevalence is currently reaching epidemic levels, thereby making HFpEF one of the greatest challenges facing cardiovascular medicine today. Compared to HF with reduced ejection fraction (HFrEF), the medical attitude in the case of HFpEF was a relaxed one towards the disease, despite the fact that it is much more complex, with many problems related to the identification of physiopathogenetic mechanisms and optimal methods of treatment. The current medical challenge is to develop effective therapeutic strategies, because patients suffering from HFpEF have symptoms and quality of life comparable to those with reduced ejection fraction, but the specific medication for HFrEF is ineffective in this situation; for this, we must first understand the pathological mechanisms in detail and correlate them with the clinical presentation. Another important aspect of HFpEF is the diversity of patients that can be identified under the umbrella of this syndrome. Thus, before being able to test and develop effective therapies, we must succeed in grouping patients into several categories, called phenotypes, depending on the pathological pathways and clinical features. This narrative review critiques issues related to the definition, etiology, clinical features, and pathophysiology of HFpEF. We tried to describe in as much detail as possible the clinical and biological phenotypes recognized in the literature in order to better understand the current therapeutic approach and the reason for the limited effectiveness. We have also highlighted possible pathological pathways that can be targeted by the latest research in this field.
Subject randomized to this arm are initially "OFF" DBS (Deep Brain Stimulation) prior to the open label period for 16 weeks and then "ON" DBS for the next 16 weeks. This is then followed by an open-label period of DBS stimulation.
Non-esterified fatty acids (NEFAs), key to energy metabolism, may become pathogenic at elevated levels, potentially eliciting immune reactions. Our laboratory's findings of reduced L-histidine in ketotic states, induced by heightened NEFA concentrations, suggest an interrelation with NEFA metabolism. This observation necessitates further investigation into the mitigating role of L-histidine on the deleterious effects of NEFAs. Our study unveiled that elevated NEFA concentrations hinder the proliferation of Bovine Mammary Epithelial Cells (BMECs) and provoke inflammation in a dose-responsive manner. Delving into L-histidine's influence on BMECs, RNA sequencing revealed 2124 genes differentially expressed between control and L-histidine-treated cells, with notable enrichment in pathways linked to proliferation and immunity, such as cell cycle and TNF signaling pathways. Further analysis showed that L-histidine treatment positively correlated with an increase in EdU-555-positive cell rate and significantly suppressed IL-6 and IL-8 levels (p < 0.05) compared to controls. Crucially, concurrent treatment with high NEFA and L-histidine normalized the number of EdU-555-positive cells and cytokine expression to control levels. Investigating the underlying mechanisms, Gab2 (Grb2-associated binder 2) emerged as a central player; L-histidine notably reduced Gab2 expression, while NEFA had the opposite effect (p < 0.05). Gab2 overexpression escalated nitric oxide (NO) production and IL6 and IL8 expression. However, L-histidine addition to Gab2-overexpressing cells resulted in NO concentrations indistinguishable from controls. Our findings collectively indicate that L-histidine can counteract NEFA-induced inflammation in BMECs by inhibiting Gab2 expression, highlighting its therapeutic potential against NEFA-related metabolic disturbances.
Probiotics can enhance broiler chicken health by improving intestinal microbiota, potentially replacing antibiotics. They protect against bacterial diseases like necrotic enteritis (NE) in poultry. Understanding their role is crucial for managing bacterial diseases, including NE. This study conducted a meta-analysis to assess the effects of Bacillus subtilis probiotic supplementation on feed conversion ratio (FCR), NE lesion score, and mortality. Additionally, a systematic review analysed gut microbiota changes in broilers challenged with Clostridium perfringens with or without the probiotic supplementation. Effect sizes from the studies were estimated in terms of standardized mean difference (SMD). Random effect models were fitted to estimate the pooled effect size and 95% confidence interval (CI) of the pooled effect size between the control [probiotic-free + C. perfringens] and the treatment [Bacillus subtilis supplemented + C. perfringens] groups. Overall variance was computed by heterogeneity (Q). The meta-analysis showed that Bacillus subtilis probiotic supplementation significantly improved FCR and reduced NE lesion score but had no effect on mortality rates. The estimated overall effects of probiotic supplementation on FCR, NE lesion score and mortality percentage in terms of SMD were -0.91 (CI = -1.34, -0.49; P < 0.001*); -0.67 (CI = -1.11, -0.22; P = 0.006*), and -0.32 (CI = -0.70, 0.06; P = 0.08), respectively. Heterogeneity analysis indicated significant variations across studies for FCR (Q = 69.66; P < 0.001*) and NE lesion score (Q = 42.35; P < 0.001*) while heterogeneity was not significant for mortality (Q = 2.72; P = 0.74). Bacillus subtilis probiotic supplementation enriched specific gut microbiota including Streptococcus, Butyricicoccus, Faecalibacterium, and Ruminococcus. These microbiotas were found to upregulate expression of various genes such as TJ proteins occluding, ZO-1, junctional adhesion 2 (JAM2), interferon gamma, IL12-β and transforming growth factor-β4. Moreover, downregulated mucin-2 expression was involved in restoring the intestinal physical barrier, reducing intestinal inflammation, and recovering the physiological functions of damaged intestines. These findings highlight the potential benefits of probiotic supplementation in poultry management, particularly in combating bacterial diseases and promoting intestinal health.
The cohort was retrospectively enrolled in The Sixth Affiliated Hospital, Sun Yat-sen University from August 2010 to August 2022. It is a training cohort.
Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Using a monoclonal antibody (MAb), chimeric, human or humanized, in which the glycan structure of the Fc region is of the two-branched type, to prepare a composition for treating patients with a CD16 polymorphism, partricularly V/F 158 or F/F 158, is new. Use of a monoclonal antibody (MAb), chimeric, human or humanized, in which the glycan structure of the Fc region is of the two-branched type, to prepare a composition for treating patients with a CD16 polymorphism, partricularly V/F 158 or F/F 158. The glycan structure has short chains; low degree of sialylation of mannose and GlcNAc at the terminal, non-intercalated point of attachment, and a low degree of fucosylation. Particularly patients are those for whom treatment with currently available antibodies has failed or who are suffering adverse side effects. ACTIVITY : Cytostatic; Antibacterial; Virucide; Schistomacide. No biological data given. MECHANISM OF ACTION : Ab induce secretion of cytokines (especially tumor necrosis factor; interferon-gamma ; IP 10 and interleukin-6) and antibody-dependent cellular cytotoxicity.
BACKGROUND: The increasing incidence of antibiotic-associated diarrhoea (AAD) is a serious health care problem. Dysbiosis of the gut microbiota is suspected to play a role in the pathogenesis of AAD, but its impact on the clinical outcomes of patients remains unclear.
METHODS: Between May and October 2022, 210 patients with AAD admitted to a university hospital and 100 healthy controls were recruited. DNA extraction from stool specimens and shotgun sequencing were performed. Machine learning was conducted to assess profiling at different taxonomic levels and to select variables for multivariable analyses.
RESULTS: Patients were classified into two groups: Clostridioides difficile infection (CDI, n = 39) and non-CDI AAD (n = 171). The in-hospital mortality rate for the patients was 20.0%, but the presence of C. difficile in the gut microbiota was not associated with mortality. Machine learning showed that taxonomic profiling at the genus level best reflected patient prognosis. The in-hospital mortality of patients was associated with the relative abundance of specific gut microbial genera rather than alpha-diversity: each of the five genera correlated either positively (Enterococcus, Klebsiella, Corynebacterium, Pseudomonas, and Anaerofustis) or negatively (Bifidobacterium, Bacteroides, Streptococcus, Faecalibacterium, and Dorea). Genes for vancomycin resistance were significantly associated with in-hospital mortality in patients with AAD (adjusted hazard ratios, 2.45; 95% CI, 1.20-4.99).
CONCLUSION: This study demonstrates the potential utility of metagenomic studies of the gut microbial community as a biomarker for prognosis prediction in AAD patients.
Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
Patients with sickle cell disease are increasingly becoming eligible for transplantation as the techniques of stem cell transplantation continue to improve, leading to less morbidity and mortality. However, the availability of a matched donor still remains one of the main obstacles. Given the inherited nature of this disease, many HLA-matched siblings of patients with sickle cell disease have sickle cell trait. Therefore, patients with sickle cell trait presumably have been used as donors for patients with sickle cell disease. However, there are no published data on whether special manipulations are required for the maintenance and storage of stem cells collected from patients with sickle cell trait. The effects of granulocyte-colony stimulating factor (G-CSF)-induced stem cell mobilization in these patients are also not known. Also, due to the potential of HbS gellation in red cells, the freezing of stem cells derived from individuals with sickle cell trait may require a more stringent red cell removal than is normally performed. We would like to evaluate these issues using volunteers with sickle cell trait prior to beginning our own transplant protocol for sickle cell disease.
Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
Naproxen itself is rapidly and completely absorbed from the GI tract with an in vivo bioavailability of 95%. Based on the pharmacokinetic profile, the absorption phase of NAPRELAN® Tablets occurs in the first 4-6 hours after administration. This coincides with disintegration of the tablet in the stomach, the transit of the sustained release microparticles through the small intestine and into the proximal large intestine. An in vivo imaging study has been performed in healthy volunteers that confirms rapid disintegration of the tablet matrix and dispersion of the microparticles.

The absorption rate from the sustained release particulate component of NAPRELAN® Tablets is slower than that for conventional naproxen sodium tablets. It is this prolongation of drug absorption processes that maintains plasma levels and allows for once daily dosing.
BACKGROUND: Obesity is associated with multiple pregnancy-related complications. Bariatric surgery is frequently performed in women of childbearing age. While the impact of bariatric surgery on fertility and nutritional complications has been characterized, few studies on effects of bariatric surgery on obesity-related pregnancy complications exist. The purpose of this study is to examine the impact of bariatric surgery on pregnancy complications in a US insured population.
METHODS: Pregnancy-related claims from 2011-2019 were obtained from MarketScan commercial claims database for bariatric surgical patients and non-surgical patients with no history of obesity. Claims were grouped into 3 time periods: pre-surgery (time of first claim to date of surgery), peri-surgery (date of surgery to 24 month postoperatively), and post-surgery (> 24 month postoperatively). Peri-surgery period was defined based on the recommendation to avoid pregnancy for the first 12-24 months following surgery. Codes for both maternal and fetal pregnancy-related complications were extracted from the database. Standardized incidence rates in person-months (pms) were calculated and generalized estimating equations with Poisson distribution tested for differences in each category at the three time intervals.
RESULTS: The final cohort included 163612 female bariatric surgery patients. The rate of successful births was 3/1000 pms in the pre-surgery and peri-surgery period and increased to 4/1000 pms in the post-surgery period, compared to a rate of 7/1000 in the control group. The rate of pregnancy complications in the pre-surgery group was 4/1000 pms and dropped to 2/1000 pms in the peri- and post-surgery periods. The complication rate in the control group was 4/1000 pms.
CONCLUSION: After bariatric surgery, the rate of pregnancy complications is lower than non-obese, non-bariatric surgery patients. Compared to before surgery, pregnancy complications decrease by 63% in the peri-surgery period and 57% in the post-surgery period. In the US, bariatric surgery is an important intervention for decreasing pregnancy complications in patients with obesity.